Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Brekke Rygh, Cecilie ^a,b   Wang, Jian ^a   Thuen, Marte ^c   Gras Navarro, Andrea ^a   Marie Huuse, Else ^c   Thorsen, Frits ^a   Poli, Aurelie ^a,d   Zimmer, Jacques ^d   Haraldseth, Olav ^c,e   Atle Lie, Stein ^a   Enger, Perøyvind ^a,b   Chekenya, Martha ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9.2.27; NATURAL KILLER CELL RECEPTOR; NEURON GLIA 2 PROTEIN; PROTEOGLYCAN; UNCLASSIFIED DRUG; ANTIGEN; CHONDROITIN SULFATE PROTEOGLYCAN 4;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; NATURAL KILLER CELL; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OSMOTIC PUMP; PROTEIN TARGETING; RAT; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CHEMISTRY; DIFFUSION; DISEASE MODEL; DRUG EFFECTS; EXTRACELLULAR FLUID; GENE EXPRESSION; GENETICS; IMAGE ENHANCEMENT; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE RAT; PATHOLOGY; TRANSPLANTATION;

RATTUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; BRAIN NEOPLASMS; DIFFUSION; DISEASE MODELS, ANIMAL; EXTRACELLULAR FLUID; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; IMAGE ENHANCEMENT; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRALESIONAL; KILLER CELLS, NATURAL; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR TARGETED THERAPY; PROTEOGLYCANS; RATS; RATS, NUDE; TUMOR BURDEN;

EID: 84907509892     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108414     Document Type: Article

References (58)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Roth JG, Elvidge AR (1962) Glioblastoma: a clinical survey. J Neurosurgery 17: 736-750.
3. McGrath DM, Bradley DP, Tessier JL, Lacey T, Taylor CJ, et al. (2009) Comparison of model-based arterial input functions for dynamic contrast-enhanced MRI in tumor bearing rats. Magn Reson Med 61: 1173-1184.
4. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972.
5. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, et al. (2013) Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 13: 347.
6. Al-Mayhani MT, Grenfell R, Narita M, Piccirillo S, Kenney-Herbert E, et al. (2011) NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro Oncol 13: 830-845.
7. Chekenya M, Enger PO, Thorsen F, Tysnes BB, Al-Sarraj S, et al. (2002) The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol 28: 367-380.
8. Chekenya M, Rooprai HK, Davies D, Levine JM, Butt AM, et al. (1999) The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. Int J Dev Neurosci 17: 421 -435.
9. Brekke C, Lundervold A, Enger PO, Brekken C, Stalsett E, et al. (2006) NG2 expression regulates vascular morphology and function in human brain tumours. Neuroimage 29: 965-976.
10. Chekenya M, Hjelstuen M, Enger PO, Thorsen F, Jacob AL, et al. (2002) NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J 16: 586-588.
11. Chekenya M, Krakstad C, Svendsen A, Nedand IA, Staalesen V, et al. (2008) The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene 27: 5182-5194.
12. Svendsen A, Verhoeff JJ, Immervoll H, Brogger JC, Kmiecik J, et al. (2011) Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 122: 495-510.
13. Behm EG, Smith FO, Raimondi SC, Pui CH, Bernstein ID (1996) Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4; 11)(q21; q23) or t(11; 19)(q23;p 13) and MLL gene rearrangements. Blood 87: 1134-1139.
14. Mauvieux L, Delabesse E, Bourquelot P, Radford-Weiss I, Bennaceur A, et al. (1999) NG2 expression in MEL rearranged acute myeloid leukaemia is restricted to monoblastic cases. Br J Haematol 107: 674-676.
15. Smith FO, Rauch C, Williams DE, March CJ, Arthur D, et al. (1996) The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 87: 1123-1133.
16. Poli A, Wang J, Domingues O, Planaguma J, Yan T, et al. (2013) Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget 4: 1527-1546.
17. Kmiecik J, Gras Navarro A, Poli A, Planaguma J, Zimmer J et al. (2014) Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma. OncoImmunology.
18. Miller JS (2002) Biology of natural killer cells in cancer and infection. Cancer Invest 20: 405 -419.
19. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678.
20. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, et al. (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 178: 597-604.
21. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, et al. (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182: 3530-3539.
22. Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, et al. (2012) Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cellmediated killing compared with serum-cultured glioblastoma cells. Brain Pathol 22: 159-174.
23. Hylton N (2006) Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24: 3293-3298.
24. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223-232.
25. Chenevert TL, Stegman ED, Taylor JM, Robertson PL, Greenberg HS, et al. (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92: 2029-2036.
26. Lyng H, Haraldseth O, Rofstad EK (2000) Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43: 828-836.
27. Festing MF, May D, Connors TA, Lovell D, Sparrow S (1978) An athymic nude mutation in the rat. Nature 274: 365-366.
28. Poli A, Brons NH, Ammerlaan W, Michel T, Hentges F, et al. (2010) Novel method for isolating untouched rat natural killer cells with higher purity compared with positive selection and fluorescence-activated cell sorting. Immunology 131: 386-394.
29. WangJ, Miletic H, Sakariassen PO, Huszthy PC, Jacobsen H, et al. (2009) A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 9: 465.
30. Brunberg JA, Chenevert TL, McKeever PE, Ross DA, Junck LR, et al. (1995) In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR AmJ Neuroradiol 16: 361-371.
31. Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, et al. (2012) In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts. J Magn Reson Imaging 35: 1098-1107.
32. Nap er C, Hayashi S, Joly E, Butcher GW, Rolstad B, et al. (2002) Ly49i2 is an inhibitory rat natural killer cell receptor for an MHC class la molecule (RT1-Alc). Fur J Immunol 32: 2031-2036.
33. Smith MM, Thompson JE, Castillo M, Cush S, Mukherji SK, et al. (1996) MR of recurrent high-grade astrocytomas after intralesional immunotherapy. AJNR Am J Neuroradiol 17: 1065-1071.
34. Floeth FW, Aulich A, Langen KJ, Burger KJ, Bock WJ, et al. (2001) MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma. AJNR Am J Neuroradiol 22: 1517-1527.
35. Abbott NJ (2004) Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 45: 545-552.
36. Matheus MG, Castillo M, Ewend M, Smith JK, Knock L, et al. (2004) CT and MR imaging after placement of the Glia Site radiation therapy system to treat brain tumor: initial experience. AJNR Am J Neuroradiol 25: 1211 -1217.
37. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280.
38. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 27: 2905-2908.
39. Finn MA, Blumenthal DT, Salzman KL, Jensen RL (2007) Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 67: 246-250; discussion 250.
40. Ulmer S, Braga TA, Barker FG 2nd, Lev MH, Gonzalez RG, et al. (2006) Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 67: 1668-1670.
41. Henegar MM, Moran CJ, Silbergeld DL (1996) Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 84: 174-179.
42. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, et al. (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217: 377-384.
43. Mills SJ, Soh C, Rose CJ, Cheung S, Zhao S, et al. (2010) Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging-derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol 31: 549-553.
44. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051.
45. Fukumura D, Jain RK (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101: 937-949.
46. Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271: 58-65.
47. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, et al. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92: 1599-1610.
48. Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo KO, et al. (2011) Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One 6: e23062.
49. Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, et al. (2006) Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Nad Acad Sci USA 103: 16466-16471.
50. Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C (2005) Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging 23: 833-841.
51. Kauppinen RA (2002) Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 15: 6-17.
52. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ (1999) Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1: 113-117.
53. Sadeghi N, Camby I, Goldman S, Gabius HJ, Baleriaux D, et al. (2003) Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. AJR Am J Roentgenol 181: 235-241.
54. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, et al. (2007) Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 25: 1-13.
55. Sadeghi N, D'Haene N, Decaestecker C, Levivier M, Metens T, et al. (2008) Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 29: 476-482.
56. Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, et al. (2011) Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging-correlation with tumor grade. Radiology 261: 882-890.
57. Seo HS, Chang KH, Na DG, Kwon BJ, Lee DH (2008) High b-value diffusion (b = 3000 s/mm2) MR imaging in cerebral gliomas at 3T: visual and quantitative comparisons with b = 1000 s/mm2. AJNR Am J Neuroradiol 29: 458 -463.
58. Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, et al. (2013) Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology 269: 831-840.